| CEO: | Jeremy Skillington |
| CFO: | Ian O’Connel |
| Executive Chairman: | Cathal Friel |
| Independent Non-Executive Director: | Brendan Buckley |
| Independent Non-Executive Director: | Edward Gibson |
| Independent Non-Executive Director: | Luke O’Neill |
| Non-Executive Dir: |
| Address: | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Phone: | +44 (0)20 7183 1499 |
| Website: | http://www.poolbegpharma.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BKPG7Z60 |
| Currency | UK Pounds |
| Share Price | 4.70p |
| Change Today | 0.050p |
| % Change | 1.08 % |
| 52 Week High | 5.55 |
| 52 Week Low | 2.40 |
| Volume | 736,296 |
| Shares Issued | 697.20m |
| Market Cap | £32.77m |
| Beta | 0.92 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 10:23 | 5,000 @ 4.40p |
| 10:22 | 87,243 @ 4.58p |
| 10:07 | 25,000 @ 4.50p |
| 10:05 | 100,000 @ 4.50p |
| 10:00 | 94 @ 4.80p |
| CEO | Jeremy Skillington |
| CFO | Ian O’Connel |
You are here: research